How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study

被引:11
作者
Belger, Mark [1 ]
Haro, Josep Maria [2 ]
Reed, Catherine [1 ]
Happich, Michael [1 ]
Kahle-Wrobleski, Kristin [3 ]
Argimon, Josep Maria [4 ]
Bruno, Giuseppe [5 ]
Dodel, Richard [6 ]
Jones, Roy W. [7 ]
Vellas, Bruno [8 ]
Wimo, Anders [9 ]
机构
[1] Eli Lilly & Co Ltd, Lilly Res Ctr, Sunninghill Rd, Windlesham GU20 6PH, Surrey, England
[2] Univ Barcelona, CIBERSAM, Parc Santari Sant Joan Deu, Barcelona, Spain
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Agcy Qualitat & Avaluacio Sanitaries, Barcelona, Spain
[5] Univ Rome Sapienza, Dept Neurol & Psychiat, Clin Memoria, Rome, Italy
[6] Univ Marburg, Dept Neurol, Marburg, Germany
[7] Royal United Hosp, RICE Res Inst Care Older People, Bath, Avon, England
[8] Toulouse Univ Hosp, Gerontopole, INSERM 1027, Toulouse, France
[9] Karolinska Inst, Dept Neurobiol, Div Neurogeriatr, Care Sci & Soc, Stockholm, Sweden
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2016年 / 16卷
关键词
Alzheimer's disease; Cost of illness; Missing data analysis; Missing data mechanisms; Multiple imputation; MULTIPLE IMPUTATION; CLINICAL-TRIALS; INFORMAL CARE; DETERMINANTS; DEMENTIA; MODERATE; RESOURCES; DESIGN; MILD;
D O I
10.1186/s12874-016-0188-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Missing data are a common problem in prospective studies with a long follow-up, and the volume, pattern and reasons for missing data may be relevant when estimating the cost of illness. We aimed to evaluate the effects of different methods for dealing with missing longitudinal cost data and for costing caregiver time on total societal costs in Alzheimer's disease (AD). Methods: GERAS is an 18-month observational study of costs associated with AD. Total societal costs included patient health and social care costs, and caregiver health and informal care costs. Missing data were classified as missing completely at random (MCAR), missing at random (MAR) or missing not at random (MNAR). Simulation datasets were generated from baseline data with 10-40 % missing total cost data for each missing data mechanism. Datasets were also simulated to reflect the missing cost data pattern at 18 months using MAR and MNAR assumptions. Naive and multiple imputation (MI) methods were applied to each dataset and results compared with complete GERAS 18-month cost data. Opportunity and replacement cost approaches were used for caregiver time, which was costed with and without supervision included and with time for working caregivers only being costed. Results: Total costs were available for 99.4 % of 1497 patients at baseline. For MCAR datasets, naive methods performed as well as MI methods. For MAR, MI methods performed better than naive methods. All imputation approaches were poor for MNAR data. For all approaches, percentage bias increased with missing data volume. For datasets reflecting 18-month patterns, a combination of imputation methods provided more accurate cost estimates (e.g. bias: -1 % vs -6 % for single MI method), although different approaches to costing caregiver time had a greater impact on estimated costs (29-43 % increase over base case estimate). Conclusions: Methods used to impute missing cost data in AD will impact on accuracy of cost estimates although varying approaches to costing informal caregiver time has the greatest impact on total costs. Tailoring imputation methods to the reason for missing data will further our understanding of the best analytical approach for studies involving cost outcomes.
引用
收藏
页数:11
相关论文
共 32 条
  • [1] [Anonymous], 1987, Statistical analysis with missing data
  • [2] Missing .... presumed at random: cost-analysis of incomplete data
    Briggs, A
    Clark, T
    Wolstenholme, J
    Clarke, P
    [J]. HEALTH ECONOMICS, 2003, 12 (05) : 377 - 392
  • [3] The design of simulation studies in medical statistics
    Burton, Andrea
    Altman, Douglas G.
    Royston, Patrick
    Holder, Roger L.
    [J]. STATISTICS IN MEDICINE, 2006, 25 (24) : 4279 - 4292
  • [4] How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?
    Coley, N.
    Gardette, V.
    Cantet, C.
    Gillette-Guyonnet, S.
    Nourhashemi, F.
    Vellas, B.
    Andrieu, S.
    [J]. CURRENT ALZHEIMER RESEARCH, 2011, 8 (04) : 421 - 433
  • [5] Methodological considerations in cost of illness studies on Alzheimer disease
    Nagede Costa
    Helene Derumeaux
    Thomas Rapp
    Valérie Garnault
    Laura Ferlicoq
    Sophie Gillette
    Sandrine Andrieu
    Bruno Vellas
    Michel Lamure
    Alain Grand
    Laurent Molinier
    [J]. Health Economics Review, 2 (1) : 1 - 12
  • [6] Determinants of societal costs in Alzheimer's disease: GERAS study baseline results
    Dodel, Richard
    Belger, Mark
    Reed, Catherine
    Wimo, Anders
    Jones, Roy W.
    Happich, Michael
    Argimon, Josep M.
    Bruno, Giuseppe
    Vellas, Bruno
    Maria Haro, Josep
    [J]. ALZHEIMERS & DEMENTIA, 2015, 11 (08) : 933 - 945
  • [7] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN
    FOLSTEIN, MF
    FOLSTEIN, SE
    MCHUGH, PR
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) : 189 - 198
  • [8] Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
    Galasko, D
    Schmitt, F
    Thomas, R
    Jin, S
    Bennett, D
    Ferris, S
    [J]. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2005, 11 (04) : 446 - 453
  • [9] Evaluation of full costs of care for patients with Alzheimer's disease in France: The predominant role of informal care
    Gerves, Chloe
    Chauvin, Pauline
    Bellanger, Martine Marie
    [J]. HEALTH POLICY, 2014, 116 (01) : 114 - 122
  • [10] Costs of care in a mild-to-moderate Alzheimer clinical trial sample: Key resources and their determinants
    Gustavsson, Anders
    Cattelin, Francoise
    Jonsson, Linus
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (04) : 466 - 473